The interaction of canonical Wnt/β-catenin signaling with protein lysine acetylation

Hongjuan You1†, Qi Li1,2†, Delong Kong1, Xiangye Liu1, Fanyun Kong1*, Kuiyang Zheng1,3 and Renxian Tang1,3*

Abstract
Canonical Wnt/β-catenin signaling is a complex cell-communication mechanism that has a central role in the progression of various cancers. The cellular factors that participate in the regulation of this signaling are still not fully elucidated. Lysine acetylation is a significant protein modification which facilitates reversible regulation of the target protein function dependent on the activity of lysine acetyltransferases (KATs) and the catalytic function of lysine deacetylases (KDACs). Protein lysine acetylation has been classified into histone acetylation and non-histone protein acetylation. Histone acetylation is a kind of epigenetic modification, and it can modulate the transcription of important biological molecules in Wnt/β-catenin signaling. Additionally, as a type of post-translational modification, non-histone acetylation directly alters the function of the core molecules in Wnt/β-catenin signaling. Conversely, this signaling can regulate the expression and function of target molecules based on histone or non-histone protein acetylation. To date, various inhibitors targeting KATs and KDACs have been discovered, and some of these inhibitors exert their anti-tumor activity via blocking Wnt/β-catenin signaling. Here, we discuss the available evidence in understanding the complicated interaction of protein lysine acetylation with Wnt/β-catenin signaling, and lysine acetylation as a new target for cancer therapy via controlling this signaling.

Keywords: Protein lysine acetylation, Canonical Wnt/β-catenin signaling, Interaction, Therapy, Molecular mechanisms
activated signals recruit Dishevelled (DVL) and Axin to the FZD-LRP5/6 co-receptors to disrupt the “destruction protein complex”. Subsequently, β-catenin is released from the complex and translocates into the cell nucleus, where β-catenin forms a complex with T cell factor (TCF)/lymphoid enhancer factor (LEF) to activate the expression of Wnt-dependent genes, including MYC as well as cyclin D1 (CCND1) genes. Also, this signaling can be inhibited by endogenous inhibitory molecules, including Wnt inhibitory factor 1 (WIF-1), Dickkopf-related protein (DKK), and secreted frizzled-related proteins (SFRPs). Particularly, WIF-1 and SFRPs directly interact with Wnts, and DKK blocks the FZD-LRP5/6 receptor complex to inhibit Wnt/β-catenin signaling [3, 4]. Furthermore, numerous cellular factors, including protein kinases [5], non-coding RNA [6], and different posttranslational modifications (PTM) [7], including phosphorylation, sumoylation, and ubiquitination, are identified to play a vital role in modulating this signaling.

As an evolutionarily conserved protein modification, lysine acetylation can transfer the acetyl group from acetyl-coenzyme A to target substrates to alter their biological functions [8]. Until now, the acetylation of histone, as well as non-histone proteins, has been discovered [9]. Also, the acetylation levels in most identified histone and non-histone proteins rely on lysine acetyltransferases (KATs, also named histone acetyltransferases, HATs), and lysine deacetylases (KDACs, also called histone deacetylases, HDACs). KATs are further divided into cytoplasmic and nuclear KATs. Recently, tubulin N-acetyltransferase 1 (TAT1) and KAT1 have been discovered to act as cytoplasmic KATs. Nuclear KATs are classified into 5 families: CREB-binding protein (CBP)/p300, basal transcription factors, MYST, general control non-repressed 5 (GCN5)/CBP-associated factor (PCAF), and nuclear receptor coactivator family. In addition, KDACs are divided into class I (HDAC1, 2, 3, 8) [8, 9], class II (HDAC4, 5, 6, 9, 10) [10, 12], class III (sirtuin (SIRT)1, 2, 3, 4, 5, 6, 7) [11], and class IV (HDAC11) [12]. Especially, it is proved that histone acetylation facilitates the transcription of target genes [8]. Non-histone protein acetylation is responsible for the modulation of various molecular functions, including protein stability and enzymatic activity [12].

Increasing evidence indicates that the protein lysine acetylation, including the acetylation of histones as well as non-histone proteins, is vital for Wnt/β-catenin signaling activation. Conversely, this signaling can regulate the protein lysine acetylation. Here, we discuss the latest advances related to protein lysine acetylation to regulate Wnt/β-catenin signaling, the effect of this signaling on controlling protein lysine acetylation, as well as the potential of targeting lysine acetylation to inhibit this signaling to facilitate cancer treatment.

The function of Wnt/β-catenin signaling in non-histone protein acetylation

As mentioned above, the effect of Wnt/β-catenin signaling in different biological processes is mainly dependent on Wnt target genes [1]. However, current evidence indicates that this signaling also controls multiple molecular functions by modulating the acetylation levels of target proteins. For example, p53 plays a fundamental role in various biological processes, but the mechanisms associated with the regulation of p53 are still not fully understood. The study by Riascos-Bernal et al. showed that β-catenin can suppress the function of p53 via inhibiting its acetylation mediated by CBP [13]. NF-κB signaling is a vital regulator of inflammation. Especially, the acetylation of RelA, a core
molecule in NF-κB signaling, could be acetylated by CBP. However, β-catenin can inhibit RelA acetylation to restrict NF-κB target gene expression in lung fibroblast and carcinoma cells to further inhibit inflammation [14].

In Wnt/β-catenin signaling, as a restriction factor, GSK3β also could regulate the acetylation levels of different molecules. Eom et al. reported that GSK3β can bind to p53, and the interaction is capable of initiating K373 and K382 acetylation in p53 [15]. However, it is still unknown which among the KATs contributes to the increase of p53 acetylation induced by GSK3β. In addition to p53, GSK3 also could interact with and phosphorylate 60 kDa Tat-interactive protein (TIP60), and then strengthen Unc51-like kinase-1 (ULK1) acetylation mediated by TIP60 to facilitate autophagy [16]. However, whether other molecules in this signaling participate in the modulation of non-histone acetylation is largely unknown.
The contribution of non-histone protein acetylation to Wnt/β-catenin signaling

So far, in Wnt/β-catenin signaling, the acetylation of four molecules, including LRP6, TCF4, GSK3β, and β-catenin has been unveiled (Fig. 1). For example, Wu et al. reported that p300 is capable of facilitating LRP6 acetylation and then triggering its phosphorylation to sensitize this signaling and further accelerate the self-renewal of colorectal cancer cells to facilitate liver metastasis [17]. As for TCF4, it has been shown that, based on CBP, the protein can be acetylated at K150. Furthermore, the conformational change of the TCF4-DNA complex can be induced by acetylated TCF4 [18]. As one component of the “destruction protein complex” in this signaling, GSK3β is also reported to be acetylated, and the results show that SIRT1, SIRT2, and SIRT3 could inhibit GSK3β to block its activity [19–21]. However, whether other molecules in the “destruction protein complex”, including CK1, Axin, and APC, are capable of being modulated by acetylation is still unclear.

To date, β-catenin acetylation has been widely explored by different groups. It has been found that β-catenin acetylation is relevant to CBP, p300, and PCAF. Especially, the acetylation of K345 in β-catenin is associated with p300 [22]. The K49 in β-catenin can be acetylated by CBP [23]. The K19 and K49 in β-catenin are the critical residues for PCAF-mediated acetylation [24]. Furthermore, β-catenin acetylation not only improves its stability by inhibiting the ubiquitin-mediated degradation [25] but also induces its nuclear translocation, to enhance its binding to TCF and further enhance the transcription of Wnt-dependent genes [22].

Moreover, dependent on HATs as mentioned above, multiple molecules are involved in modulating β-catenin acetylation. For instance, Li et al. found that blocking proliferation 1 (BOP1) can initiate β-catenin acetylation that is dependent on CBP to strengthen the drug resistance of breast cancer [26]. Forkhead box protein P1 (FOXP1) has been proven to activate this signaling by increasing β-catenin acetylation in different biological processes [27, 28]. Especially, in B cell lymphoma, FOXP1 can enhance β-catenin acetylation through CBP. Next, the increased acetylation of β-catenin benefits the gene transcription mediated by FOXP1 [28]. In addition to BOP1 and FOXP1, Zhang et al. found that cell-cycle related and expression-elevated protein in tumor (CREPT) facilitates colorectal cancer growth by enhancing p300-mediated β-catenin acetylation [29]. In addition, high glucose-dependent β-catenin nuclear retention also requires p300-dependent β-catenin acetylation at K354 to trigger the increase of MYC as well as CCND1 genes in multiple cancers [30]. Also, ATP citrate lyase (ACLY) is found to affect β-catenin acetylation at K49 in hepatoma carcinoma (HCC) cells [31]. Additionally, Wnt1 and Wnt7b [32] also can accelerate β-catenin acetylation at K49. However, it is still unknown which of the HATs contribute to β-catenin acetylation mediated by Wnt molecules.

Although several molecules mentioned above contribute to β-catenin acetylation, current reports show that other cellular factors can inhibit the acetylation of β-catenin by suppressing KATs. For example, the transcription factor Kruppel-like factor 4 (KLF4) is critical for intestinal differentiation. Moreover, the differentiation mediated by KLF4 is observed to rely on its interaction with β-catenin to inhibit acetylation of the protein mediated by p300/CBP [33]. The nuclear factor of activated T-cells 5 (NFAT5) is also verified to take participate in repressing Wnt/β-catenin signaling. Especially, NFAT5
directly binds to β-catenin and inhibits the interaction of β-catenin with CBP to block its acetylation [34].

Apart from KATs, many molecules are capable of restricting β-catenin acetylation by KDACs, including SIRT1, SIRT2, HDAC1, HDAC4, HDAC6, and HDAC7. For example, in bladder cancer cells, Capsaicin can attenuate cell migration via SIRT1-dependent inhibition of β-catenin acetylation [35]. Additionally, it is observed that the expression of β-catenin is increased in liver cancer stem cells (LCSCs) and its expression is particularly associated with SIRT1. Moreover, the decrease of β-catenin acetylation mediated by SIRT1 can regulate the self-renewal of LCSCs [36]. Also, SIRT1 can deacetylate β-catenin to block the transcription of Wnt-dependent genes and regulate cell differentiation [37–39]. In addition to SIRT1, SIRT2 also could inhibit β-catenin acetylation to suppress the levels of MYC and CCND1 [40].

Recently, Chen et al. reported that B-cell lymphoma 3 (Bcl-3) can maintain K49 acetylation in β-catenin. Mechanistically, Bcl-3-dependent suppression of interaction between HDAC1 and β-catenin is associated with increased β-catenin acetylation in colorectal cancer [41]. Also, HDAC4 can inhibit β-catenin acetylation to increase its ubiquitination [42]. Interestingly, in breast cancer cells, it has been found that HDAC6 not only can inhibit K49 acetylation in β-catenin but also facilitate K345 acetylation suppression in β-catenin [43, 44]. Additionally, the interaction of HDAC7 with β-catenin also causes a decrease of K49 acetylation in β-catenin in glioma cells [45].

The influence of Wnt/β-catenin signaling on histone acetylation

As mentioned, after Wnt/β-catenin signaling sensitization, β-catenin can interact with and activate TCF/LEF, which is also controlled by various transcriptional coregulators, including the coactivators and corepressors, at the target gene promoter in the cell nucleus [46, 47]. Without Wnt signals, TCF/LEF binds to HDAC1 and HDAC2, and causes histone H3 hypo-acetylation at the promoters of Wnt-dependent genes, and induces suppression of gene transcription [48–51]. Moreover, HDACs are capable of inhibiting β-catenin by enhancing its degradation, and inhibiting its nuclear translocation to regulate downstream gene transcription (Fig. 2) [52]. Also, SIRT6, one component of HDACs, can bind to β-catenin, resulting in histone H3K56 deacetylation to prevent gene transcription [51]. In addition to HDAC1, HDAC2, and SIRT6, whether other constituents of HDACs take part in the transcriptional inhibition through regulating the function of β-catenin or TCF/LEF is not fully clarified.

Upon activation by Wnt molecules, β-catenin is capable of interacting with TCF/LEF and disrupting the interaction of TCF/LEF with HDACs to form an active transcriptional complex in the cell nucleus (Fig. 2). Meanwhile, β-catenin can recruit p300/CBP to the transcriptional complex. In turn, p300/CBP acts as the transcriptional coactivator of β-catenin to induce histone H4 acetylation and stimulate gene transcription [53, 54]. As a chromatin effector, Pygopus 2 (Pygo2) is capable of being acetylated by the protein complex composed of CBP and p300. In the nucleus, when Pygo2 binds to the β-catenin-TCF/LEF complex, the acetylation of Pygo2 facilitates histone H3/H4 acetylation by recruiting CBP/p300 and GCN5 to activate gene transcription [55]. In HCC cells, A-kinase interacting protein 1 (AKIP1) can bind to β-catenin and maintain its accumulation in the cell nucleus by suppressing its binding to APC. Moreover, AKIP1 has the
capability of enhancing β-catenin activation and leading to the recruitment of CBP to activate gene transcription [56].

However, in the nucleus, BTB domain and CNC homolog 1 (Bach1) is found to directly bind to TCF4, and the interaction not only reduces the binding of β-catenin to TCF4 but also decreases the interaction of p300/CBP with β-catenin to inhibit histone acetylation. Furthermore, Bach1 can occupy the TCF4-binding site and recruit HDAC1 to the target genes promoter [57]. BarH-like Homeobox 2 (Barx2) and paired box 7 (Pax7) are recently identified components of the TCF/LEF transcriptional complex. After Wnt3a stimulation, Barx2 can be recruited to TCF/LEF binding sites with glutamate receptor interacting protein 1 (GRIP-1) at the Axin2 promoter, and further recruit β-catenin to induce H3 acetylation in myoblasts. In contrast, dependent on the interaction with corepressor HDAC1, Pax7 is able to repress Axin2 promoter activity, through inhibiting H3 acetylation at the promoter of Axin2 mediated by Barx2 at the transcriptional complex [58]. In myoblasts, Wnt3a not only induces expression of Barx2 at the gene level but also stabilizes Barx2 at the protein level to facilitate Axin2 expression. Conversely, Wnt3a can suppress Pax7 protein expression to induce transcription of the Wnt target gene Axin2.
The impact of histone acetylation on Wnt/β-catenin signaling

To date, increasingly studies have indicated that the activation of histone acetylation at Wnt, β-catenin, and FZD promoters can control their transcription (Table 1). In detail, the results from Jing et al. show that the levels of histone H3K9 acetylation at Wnt1, Wnt10a, Wnt6, and Wnt10b promoters are decreased in bone marrow-derived mesenchymal stem cells (BMSCs). Conversely, GCN5 is observed to be responsible for the differentiation of BMSCs by increasing H3K9 acetylation at the promoters of these Wnt genes to facilitate Wnt/β-catenin signaling activation [59]. As for β-catenin, Huang et al. found that, by interacting with the β-catenin promoter, HDAC1 can inhibit its expression in mouse embryonic fibroblasts (MEF, C3H10T1/2 cells). However, it is still unclear which histones at the promoter of β-catenin could be regulated by HDAC1 to suppress its gene expression [60]. In an Alzheimer's disease mouse model, the nuclear paraspeckle assembly transcript 1 (NEAT1) can enhance FZD3 transcription by increasing the acetylation of H3K27 at its promoter. Mechanistically, based on NEAT1, P300 could be recruited to the FZD3 promoter and enhance the transcription of the FZD3 gene through histone H3K27 acetylation [61]. Additionally, Liu et al. found that SIRT6 can interact with FZD4 and suppresses FZD4 transcription by decreasing histone H3K9 acetylation in hepatoblastoma cells [62].

In contrast, histone acetylation at several endogenous inhibitory proteins, including WIF-1, SFRP, and DKK1, can regulate the expression of these molecules to inhibit Wnt/β-catenin signaling. For example, WIF-1 expression can be silenced by suppression of histone acetylation. Following treatment with trichostatin A (TSA), the expression of WIF1 is restored. Furthermore, HDAC3 may contribute to the restriction of histone acetylation at the promoter of WIF-1 to block its expression [63]. In HCC with hepatitis C virus (HCV) infection, based on HDAC1, the viral core protein could silence SFRP1 expression by inhibiting histone H3 acetylation [64]. After treatment of glioblastoma cells with TSA, the acetylated histone H3 is increased at the promoters of WIF-1, SFRP1, and DKK1 [65]. However, SIRT1 can suppress H3K9 and H4K16 acetylation to restrict SFRP1 and SFRP2 mRNA expression [38].

In breast cancer, it was found that prostate tumor overexpressed-1 (PTOV1) can suppress transcription of DKK1 by recruiting HDAC1 and HDAC2 and decreasing histone H3/H4 acetylation levels at the DKK1 promoter [66]. Li et al. observed that, through initiating acetylation of H3K9 and H3K14 at the DKK1 promoter, GCN5 could promote DKK1 expression to modulate periodontal ligament stem cell differentiation [67]. Furthermore, in breast cancer, chromobox protein homolog 7 (CBX7) is observed to enhance the expression of DKK1. Notably, CBX7 can recruit p300/CBP to the DKK1 promoter to increase histone H3 acetylation [68]. In colon cancer SW480 cells, Genistein was found to affect histone H3 acetylation at the DKK1 promoter [69]. Additionally, Niu et al. observed that epidermal growth factor (EGF) initiates DKK1 expression in HCC cells by increasing histone H3 acetylation through p300 [70] (Table 1). Together, these studies suggest that histone acetylation at the promoters of endogenous inhibitory molecules can promote expression of these gene to suppress Wnt/β-catenin signaling, which means that the deacetylation of histone at the promoters of these molecules is in favor of Wnt/β-catenin signaling.
Targeting protein acetylation to suppress Wnt/β-catenin signaling

Given that KATs and KDACs can modulate protein acetylation, compounds with the function of blocking the activity of KATs or KDACs have important therapeutic potential for diseases involving dysfunction of protein acetylation. To date, numerous KAT inhibitors and KDAC inhibitors have been discovered, and some of these inhibitors have been approved for tumor treatment or undergone clinical trials to explore their exact clinical effect on a variety of cancers [10, 71]. Our review presented here indicates that not only acetylation but also deacetylation of certain proteins can modulate Wnt/β-catenin signaling. Especially, it has been demonstrated that acetylation or deacetylation of the target molecules is regulated by different KATs or KDACs. It is reasonable to speculate that the use of both KAT inhibitors and KDAC inhibitors can restrict this signaling to facilitate the treatment of various cancers.

Consistent with the above speculation, current data indicate that some KAT inhibitors can suppress this signaling (Table 2). Especially, curcumin [72], the active compound of turmeric or Curcuma longa L, with the function of targeting P300, could decrease the growth of HCC cells through regulating the Wnt/β-catenin pathway. Moreover, the clinical applications of curcumin in suppressing multiple cancers, including breast cancer, colorectal cancer, and pancreatic cancer have undergone Phase I/II clinical trials [73].

| Table 1 Histone acetylation and modulation of molecules in Wnt/β-catenin signaling |
|-------------------------------------------------|-------------------------------|-----------------|------------------|-----------------|-----------------|
| Histone modifier | Histone modification | Target gene | Effect on target genes | Target cells or models | References |
|-------------------|----------------------|--------------|------------------------|------------------------|-------------|
| GCN5              | H3K9Ac               | Wnt1         | Activation             | BMSCs                  | [59]        |
| GCN5              | H3K9Ac               | Wnt10a       | Activation             | BMSCs                  | [59]        |
| GCN5              | H3K9Ac               | Wnt6         | Activation             | BMSCs                  | [59]        |
| GCN5              | H3K9Ac               | Wnt10b       | Activation             | BMSCs                  | [59]        |
| HDAC1             | unknown              | β-catenin    | Inhibition             | MEFs                   | [60]        |
| P300              | H3K27Ac              | FZD3         | Activation             | Alzheimer's disease mouse model | [61] |
| SIRT6             | H3K9Ac               | FZD4         | Inhibition             | Hepatoblastoma cells   | [62]        |
| HDAC3             | unknown              | WIF-1        | Inhibition             | Fibroblasts            | [63]        |
| HDAC1             | H3Ac                 | SFRP1        | Inhibition             | HCC cells              | [64]        |
| SIRT1             | H3K9Ac               | SFRP1        | Inhibition             | MEFs                   | [38]        |
| SIRT1             | H4K16Ac              | SFRP1        | Inhibition             | MEFs                   | [38]        |
| SIRT1             | H3K9Ac               | SFRP2        | Inhibition             | MEFs                   | [38]        |
| HDAC1             | H3Ac                 | DKK1         | Inhibition             | Breast cancer cells    | [66]        |
| HDAC2             | H3Ac                 | DKK1         | Inhibition             | Breast cancer cells    | [66]        |
| HDAC1             | H4Ac                 | DKK1         | Inhibition             | Breast cancer cells    | [66]        |
| HDAC2             | H4Ac                 | DKK1         | Inhibition             | Breast cancer cells    | [66]        |
| GCN5              | H3K9Ac               | DKK1         | Activation             | Periodontal ligament stem cells | [67] |
| GCN5              | H3K14Ac              | DKK1         | Activation             | Periodontal ligament stem cells | [67] |
| p300              | H3Ac                 | DKK1         | Activation             | Breast cancer cells, HCC cells | [68, 70] |
| CBP               | H3Ac                 | DKK1         | Activation             | Breast cancer cells    | [68]        |

Ac: acetylation
Garcinol, an extract of the traditional Chinese medicine *Garcinia indica* [74, 75], also targets P300 and restricts the signaling in non-small cell lung carcinomas and breast cancer cells. However, the therapeutic potential of garcinol in inhibiting different cancers in clinical has not been reported. ICG-001, or the structural derivative PRI-724, can suppress CBP/β-catenin in several tumor cells as well (Table 2). In addition, application of this compound in inhibiting cancer was investigated in a Phase I/II clinical trial [76–86].

Furthermore, several histone deacetylase inhibitors, including TSA [10, 87–89], an inhibitor of class I, II, and IV HDACs, can target Wnt/β-catenin signaling. However, the clinical potential of this compound for the inhibition of cancers is unknown. Sodium butyrate [10, 90, 91] and valproic acid [10, 92–94], both of which target class I, and II HDACs, have been approved by the Food and Drug Administration (FDA), and also can suppress cancer by targeting this signaling. MGCD0103, also known as mocetinostat [95], is an inhibitor of Class I and IV HDACs and underwent a Phase II trial for treating cancers; it has the role of blocking Wnt/β-catenin signaling as well. Additionally, chidamide [10, 96], an inhibitor of class I and IV HDACs, is approved in China to treat cancer and can target Wnt/β-catenin signaling in cancer (Table 2). However, the molecular mechanisms related to this signaling inhibition mediated by these inhibitors in most cancers are not well clarified.

Conclusions

The canonical Wnt/β-catenin pathway is a conserved signaling mechanism that modulates a variety of physiological and pathological processes. Especially, canonical Wnt/β-catenin signaling is often hyperactivated in cancers and has a significant role in the occurrence and progression of the disease [1, 2, 97, 98]. The clinical implications of potent drugs targeting this signaling to inhibit different tumors have been assessed [99–101], and the current pharmacological intervention mainly focuses on inhibiting Wnt molecules and their receptors, stabilizing the “destruction protein complex” of β-catenin, blocking the activity of β-catenin, as well as suppressing the interaction of β-catenin with its co-factors [100, 101]. However, the molecular mechanism related to the modulation of Wnt/β-catenin signaling in different types of tumor is complicated. To better target this signaling in clinical treatment, a more thoroughly understanding of the cellular factors that benefit the regulation of this signaling is needed.

As mentioned, protein lysine acetylation involves histone acetylation and non-histone acetylation. Histone acetylation is a vital epigenetic process that critically facilitates the control of gene expression. Additionally, as a very important type of PTM, non-histone acetylation can influence the expression and activity of target proteins. The reviewed studies presented here reveal that Wnt/β-catenin signaling has a significant role in the modulation of two types of protein lysine acetylation. Conversely, protein lysine acetylation not only modulates the expression of important molecules in this signaling by histone acetylation but also directly regulates the function of these signaling-related core proteins to control its activation. To our knowledge, although the available data have demonstrated the cross-regulation between this signaling and protein lysine acetylation as mentioned above, our information on the detailed interaction between the
constituents of Wnt/β-catenin signaling with protein lysine acetylation, including histone acetylation as well as non-histone protein acetylation, remains limited. Therefore, additional research focusing on the interplay of Wnt/β-catenin signaling with protein lysine acetylation is required to deeply understand their coordinated roles and related mechanisms.

Generally, protein lysine acetylation relies on the balance of catalytic activity in KATs and KDACs. So far, a variety of KAT inhibitors and KDAC inhibitors have been identified [10, 71], and some of these identified inhibitors have been approved for targeting different cancers in clinical. Moreover, our reviewed studies suggest that many of these inhibitors can inhibit the development of different cancers by blocking this signaling. However, the information on the suppression of this signaling mediated by these inhibitors is mainly from in vitro cell models [71–96]. Data from animal experiments, as well as clinical trials, are needed to confirm whether the anticancer effect of these inhibitors

**Table 2** Information on KAT inhibitors and KDAC inhibitors to suppress Wnt/β-catenin signaling

| Drug name   | KAT or HDAC specificity | Clinical stage in treating cancer | Target cancer cell models                                                                 | Effect on Wnt/β-catenin signaling | References       |
|-------------|-------------------------|----------------------------------|------------------------------------------------------------------------------------------|----------------------------------|-----------------|
| Curcumin    | KAT inhibitor           | Phase I/II                        | HCC, Breast cancer, Chronic myeloid leukemia, Colorectal cancer, Colon carcinoma, Intestinal adenoma, Pancreatic cancer, Ovarian carcinoma, Head and neck squamous cell carcinoma| Inhibition                       | [72, 73]        |
| Garcinol    | KAT inhibitor           | Preclinical                       | Non-small cell lung carcinomas, Breast cancer                                             | Inhibition                       | [74, 75]        |
| ICG-001     | KAT inhibitor           | Phase I/II                        | Osteosarcoma, Pancreatic cancer, HCC, Nasopharyngeal carcinoma, Uveal melanoma, Colorectal cancer, Lung cancer, glioma, Myeloma, Gastric cancer, Acute lymphoblastic leukemia | Inhibition                       | [4,76–86]       |
| TSA         | HDAC inhibitor          | Preclinical                       | Pituitary adenoma, Colorectal carcinoma, HCC                                           | Inhibition                       | [10, 87–89]     |
| Sodium butyrate | HDAC inhibitor         | FDA approved                      | Gastric cancers, Colon carcinoma                                                          | Inhibition                       | [10, 90, 91]    |
| Valproic acid | HDAC inhibitor          | FDA approved                      | Glioma, Bladder cancer, Acute T lymphoblastic leukemia                                     | Inhibition                       | [10, 92–94]     |
| MGCD0103    | HDAC inhibitor          | Phase II trial                    | Colon cancer                                                                              | Inhibition                       | [10, 95]        |
| Chidamide   | HDAC inhibitor          | Approved in China                 | B cell acute lymphocytic leukemia                                                          | Inhibition                       | [10, 96]        |
is related to Wnt/β-catenin signaling. Furthermore, given the critical role of lysine acetylation on the modulation of Wnt/β-catenin signaling, a better understanding of the roles and associated mechanisms linked to protein lysine acetylation to facilitate this signaling activation may give us a unique opportunity to treat cancers.

Abbreviations
APC: Adenomatous polyposis coli; BMSCs: Bone marrow-derived mesenchymal stem cells; CK1: Casein kinase 1; KATs: Lysine acetyltransferases; HATs: Lysine deacetylases; KDACs: Histone deacetylases; HCC: Hepatoma carcinoma; BMSCs: Bone marrow-derived mesenchymal stem cells; HCV: Hepatitis C virus; LEF: Lymphoid enhancer factor; GSK3β: Glycogen synthase kinase 3β; β-TRCP: Beta-transducin repeat-containing protein; FZD: Frizzled proteins; LRP: Lipoprotein receptor-related protein; TCF: T cell factor; WIF-1: Wnt inhibitory factor 1; DKK: Dickkopf-related protein; SFRPs: Secreted frizzled-related proteins; TAT1: Tubulin N-acetyltransferase 1; CBP: CREB-binding protein; GCN5: General Control Non-repressed 5; TIP60: 60 KDa Tat-interactive protein; ULK1: Unc51-like kinase-1; BOP1: Block of proliferation 1; FOXP1: Forkhead box protein P1; CREPT: Cell-cycle related and expression-elevated protein in tumor; ACLY: ATP citrate lyase; PCAF: P300/CBP-associated factor; XLA: Kruppel-like factor 4; NFAT5: Nuclear factor of activated T-cells 5; LCSCs: Liver cancer stem cells; Bcl-3: B-cell lymphoma 3; Pygo2: Pygopus 2; AKIP1: A-kinase interacting protein 1; Barx2: A.H-like Homeobox 2; Pax7: Paired box 7; GRIP-1: Glutamate receptor interacting protein 1; MEF: Mouse embryonic fibroblasts; PTEN: Prostate tumor overexpressed-1; CBX7: Chromobox protein homolog.

Acknowledgements
The figures used in the study were created by BioRender (https://biorender.com/).

Authors’ contributions
HY and QL contributed equally to this study. HY, QL, XL, and DK wrote the manuscript and designed the artwork. FK, KZ, and RT supervised and revised the manuscript. All authors read and approved the final manuscript.

Funding
The study was supported by the Natural Science Foundation of Jiangsu Province (BK20211347), Xuzhou Technology Bureau Foundation (KCKZ202108), the Natural Science Foundation of the Jiangsu Higher Education Institutions (21KJA310004), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, China. 2 Laboratory Department, The People’s Hospital of Funing, Yancheng, Jiangsu, China. 3 National Demonstration Center for Experimental Basic Medical Sciences Education, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Received: 8 September 2021   Accepted: 29 December 2021
Published online: 15 January 2022

References
1. Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021;21:5–21.
2. Hiremath IS, Goel A, Warrier S, Kumar AP, Sethi G, Garg M. The multidimensional role of the Wnt/beta-catenin signaling pathway in human malignancies. J Cell Physiol. 2021. https://doi.org/10.1002/jcp.30561.
3. Schunk SJ, Floege J, Fiser D, Speer T. WNT-beta-catenin signalling - a versatile player in kidney injury and repair. Nat Rev Nephrol. 2021;17:172–84.
4. Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JJG, et al. Wnt-beta-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16:121–36.
5. Li Q, Sun M, Wang M, Feng M, Yang F, Li L, et al. Dysregulation of Wnt/beta-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci. 2021;112:695–706.
6. Farooqi AA, Nayyab S, Martinelli C, Berardi R, Katifelis H, Gauzori M, et al. Regulation of Hippo, TGFβ/SMAD, Wnt/beta-catenin, JAK/STAT, and NOTCH by long non-coding RNAs in pancreatic cancer. Front Oncol. 2021;11:657965.

7. Gao C, Xiao G, Hu J. Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell Biosci. 2014;4:13.

8. Ali I, Conrad RJ, Verdin E, Ott M. Lysine acetylation goes global: from epigenetics to metabolism and therapeutics. Chem Rev. 2018;118:1216–52.

9. Verdin E, Ott M. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol. 2015;16:258–64.

10. Li P, Ge J, Li H. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. Nat Rev Cardiol. 2020;17:96–115.

11. Menzies KJ, Zhang H, Katsyuba E, Auswerx J. Protein acetylation in metabolism - metabolites and cofactors. Nat Rev Endocrinol. 2016;12:43–60.

12. Nair F, Weinert B, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Drug Disc. 2018;17:657–70.

13. Rascos-Bernal DF, Chinnasamy P, Cao LL, Dunaway CM, Valenta T, Basler K, et al. beta-Catenin C-terminal signals suppress p33 and are essential for artery formation. Nat Commun. 2016;7:12339.

14. Ma B, Fey M, Hottinger MO. WNT/beta-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-kappaB target genes. J Cell Sci. 2015;128:2430–6.

15. Eom TY, Jope RS. GSK3 beta N-terminus binding to p53 promotes its acetylation. Mol Cancer. 2009;8:14.

16. Lin SY, Li TY, Liu Q, Zhang C, Li X, Chen Y, et al. GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science. 2012;336:477–81.

17. Wu Z, Wei D, Gao W, Xu Y, Hu Z, Ma Z, et al. TPO-induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110+ tumor-initiating cells. Cell Stem Cell. 2015;17:49–57.

18. Efferth S, Weise A, Brusek K, Binosiek ML, Jagle S, Senghaas N, et al. Acetylation of human TCF4 (TCF7L2) proteins attenuates inhibition by the HBp1 repressor and induces a conformational change in the TCF4-DNA complex. PLoS ONE. 2013;8:e61867.

19. Kim JY, Yang JH, Kim EJ. SIRT1 and AROS suppress doxorubicin-induced apoptosis via inhibition of GSK3beta activity in neuroblastoma cells. Anim Cells Syst (Seoul). 2020;24:53–9.

20. Xin Y, Jin Y, Ge J, Huang Z, Han L, Li C, et al. Involvement of SIRT3-GSK3beta deacetylation pathway in the effects of maternal diabetes on oocyte meiosis. Cell Profil. 2021;54:e12940.

21. Sarikhan M, Mishra S, Maity S, Kotyada C, Wolfganghe J, Gupta MP, et al. SIRT2 deacetylates the activity of GSK3 isoforms independent of inhibitory phosphorylation. Elife. 2018;7:e32952.

22. Levy L, Wei Y, Lablate C, Wu Y, Renard CA, Buendia MA, et al. Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol. 2004;24:3404–14.

23. Wolf D, Rodova M, Miska EA, Calvet JP, Kourzides T. Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem. 2002;277:23556–7.

24. Ge X, Xin Q, Zhang F, Yan T, Zhou Q, PCAF acetylates (beta)-catenin and improves its stability. Mol Biol Cell. 2009;20:419–27.

25. Liu E, Zhou Q, Xie AJ, Li X, Li M, Ye J, et al. Tau acetylates and stabilizes beta-catenin thereby promoting cell survival. EMBO Rep. 2020;21:e48328.

26. Li S, Wu H, Huang X, Jian Y, Kong L, Xu H, et al. BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated beta-catenin acetylation. J Pathol. 2021;254:265–78.

27. Shao X, Wei X, FOXP1 enhances fibrosis via activating Wnt/beta-catenin signaling pathway in endometriosis. Am J Transl Res. 2018;10:3610–8.

28. Walker MP, Stopford CM, Cederlund M, Fang F, Jahn C, Rabinowitz AD, et al. FOXP1 potentiates Wnt/beta-catenin signaling in diffuse large B cell lymphoma. Sci Signal. 2015;8(362):ra12.

29. Zhang Y, Wang S, Kang W, Liu C, Dong Y, Ren F, et al. CREPT facilitates colorectal cancer growth through inducing Wnt/beta-catenin pathway by enhancing p300-mediated beta-catenin acetylation. Oncogene. 2018;37:3485–500.

30. Chocarro-Calvo A, Garcia-Martinez JM, Aridla-Gonzalez S, De la Viela A, Garcia-Jimenez C. Glucose-induced beta-catenin acetylation enhances Wnt signaling in cancer. Mol Cell. 2013;49:474–86.

31. Han Q, Chen CA, Yang W, Liang D, Lv HW, Lv GS, et al. ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/beta-catenin signaling pathway. Hepatobiliary Pancreat Dis Int. 2021;20:251–61.

32. Alok A, Lei Z, Jagnannath NS, Kaur S, Harmston N, Rozen SG, et al. Wnt proteins synergize to activate beta-catenin signaling. J Cell Sci. 2017;130:1532–44.

33. Evans FM, Chen X, Zhang W, Liu C, KLF4 interacts with beta-catenin/TCF4 and blocks p300/CBP recruitment by beta-catenin. Mol Cell Biol. 2010;30:372–81.

34. Wang Q, Zhou Y, Rychahou P, Liu C, Weiss HL, Evers BM. N-FAT5 represses canonical Wnt signaling via inhibition of beta-catenin acetylation and participates in regulating intestinal cell differentiation. Cell Death Dis. 2013;4:e6671.

35. Islam A, Yang YT, Wu WH, Chueh PJ, Lin MH. Capsaicin attenuates cell migration via SIRT1 targeting and inhibition to enhance cortactin and beta-catenin acetylation in bladder cancer cells. Am J Cancer Res. 2019;9:1172–82.

36. Chen X, Huan H, Liu C, Luo Y, Shen J, Zhou Y, et al. Deacetylation of beta-catenin by SIRT1 regulates self-renewal and oncogenesis of liver cancer stem cells. Cancer Lett. 2019;463:1–10.

37. Feng G, Zheng K, Song D, Xu K, Huang D, Zhang Y, et al. SIRT1 was involved in TNF-alpha-promoted osteogenic differentiation of human DPSCs through Wnt/beta-catenin signal. In Vitro Cell Dev Biol Anim. 2016;52:1001–11.

38. Zhou Y, Song T, Peng J, Zhou Z, Wei H, Zhou R, et al. SIRT1 suppresses adipogenesis by activating Wnt/beta-catenin signaling in vivo and in vitro. Oncotarget. 2016;7:77707–20.

39. Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, et al. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating beta-catenin. EMBO Mol Med. 2013;5:430–40.

40. Li C, Zhou Y, Rychahou P, Weiss HL, Lee EY, Perry CL, et al. SIRT2 contributes to the regulation of intestinal cell proliferation and differentiation. Cell Mol Gastroenterol Hepatol. 2020;10:43–57.
41. Chen X, Wang C, Jiang Y, Wang Q, Tao Y, Zhang H, et al. Bcl-3 promotes Wnt signaling by maintaining the acetylation of beta-catenin at lysine 49 in colorectal cancer. Signal Transduct Target Ther. 2020;5:52.

42. Ko JY, Chuang PC, Chen MW, Ke HC, Wu SL, Chang YH, et al. MicroRNA-29a ameliorates glucocorticoid-induced suppression of osteoblast differentiation by regulating beta-catenin acetylation. Bone. 2013;57:468–75.

43. Iaconelli J, Huang JH, Berkovitch SS, Chattopadhyay S, Mazitschek R, Schreiber SL, et al. HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of beta-catenin in human iPSC-derived neuronal cells. ACS Chem Biol. 2015;10:883–90.

44. Wang SH, Li N, Wei Y, Li QR, Yu ZP. Beta-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells. Mol Med Rep. 2014;9:733–8.

45. Yu X, Wang M, Wu J, Han Q, Zhang X. ZHF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway. J Exp Clin Cancer Res. 2019;38:40.

46. Soderholm S, Cantu C. The WNT/beta-catenin dependent transcription: a tissue-specific business. WIREs Mech Biol. 2019;13(3):e1511.

47. Bian J, Dannappel M, Wan C, Firestein R. Transcriptional regulation of Wnt/beta-catenin pathway in colorectal cancer. Cells. 2020;9(9):2125.

48. Ng CP, Littman DR. Tcf1 and Lef1 pack their own HDAC. Nat Immunol. 2016;17:615–6.

49. Liu C, Zhang Y, Li J, Wang Y, Ren F, Zhou Y, et al. p15RS/RPRD1A (p15INK4b-related sequence/regulation of nuclear pre-mRNA domain-containing protein 1A) interacts with HDAC2 in inhibition of the Wnt/beta-catenin signaling pathway. J Biol Chem. 2015;290:9071–13.

50. Wang H, Diao D, Shi Z, Zhu X, Gao Y, Gao S, et al. SRT6 controls hematopoietic stem cell homeostasis through epigenetic regulation of Wnt signaling. Cell Stem Cell. 2016;18:495–507.

51. Cai J, Liu Z, Huang X, Shu S, Hu X, Zheng M, et al. The deacetylase siruin 6 protects against kidney fibrosis by epigenetically blocking beta-catenin target gene expression. Kidney Int. 2020;97:106–18.

52. Shen X, Xu L, Zhang Y, Liu L, Lin J, Chen H, et al. ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/beta-catenin signaling pathway. Carcinogenesis. 2019;40:1405–14.

53. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 2000;19:1839–50.

54. He H, Du F, He Y, Wei Z, Meng C, Xu Y, et al. The Wnt/beta-catenin signaling regulated MRTF-A transcription to activate migration-related genes in human breast cancer cells. Oncotarget. 2018;9:15239–51.

55. Andrews PG, Kao KR. Wnt/beta-catenin-dependent acetylation of Pygo2 by CBP/p300 histone acetyltransferase family members. Biochem J. 2016;473:4193–203.

56. Cui Y, Wu X, Lin C, Zhang X, Ye L, Ren L, et al. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/beta-catenin/CBP signaling pathway. Oncogene. 2019;38:5516–29.

57. Jiang L, Yin M, Wei X, Liu J, Wang X, Niu C, et al. Bach1 represses Wnt/beta-catenin signaling and angiogenesis. Circ Res. 2015;117:364–75.

58. Hulin JA, Nguyen TD, Cui S, Marri S, Yu RT, Downes M, et al. Bank2 and Pax7 regulate axin2 expression in myoblasts by interaction with beta-catenin and chromatin remodelling. Stem Cells. 2016;34:2169–82.

59. Jing H, Su X, Gao B, Shuai Y, Chen J, Deng Z, et al. Epigenetic inhibition of Wnt pathway suppresses osteogenic differentiation of BMSCs during osteoporosis. Cell Death Dis. 2020;13:1511.

60. Huang X, Xu J, Huang M, Li J, Dai L, Dai K, et al. Histone deacetylase1 promotes TGF-beta1-mediated early Lys49 acetylation and membrane localization of beta-catenin in human iPSC-derived neuronal cells. J Anat. 2015;226:587–97.

61. Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X, et al. Epigenetics and HEC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene. 2014;33:3826–35.

62. Foltz G, Yoon JG, Lee H, Ma L, Tian Q, Hood L, et al. Epigenetic regulation of Wnt pathway antagonists in human pancreatic cancer cells. J Biol Chem. 2015;290:3002–13.

63. Cui Y, Wu X, Lin C, Zhang X, Ye L, Ren L, et al. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/beta-catenin/CBP signaling pathway. Oncogene. 2019;38:5516–29.

64. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 2000;19:1839–50.

65. He H, Du F, He Y, Wei Z, Meng C, Xu Y, et al. The Wnt/beta-catenin signaling regulated MRTF-A transcription to activate migration-related genes in human breast cancer cells. Oncotarget. 2018;9:15239–51.

66. Andrews PG, Kao KR. Wnt/beta-catenin-dependent acetylation of Pygo2 by CBP/p300 histone acetyltransferase family members. Biochem J. 2016;473:4193–203.

67. Cui Y, Wu X, Lin C, Zhang X, Ye L, Ren L, et al. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/beta-catenin/CBP signaling pathway. Oncogene. 2019;38:5516–29.

68. Jing H, Su X, Gao B, Shuai Y, Chen J, Deng Z, et al. Epigenetic inhibition of Wnt pathway suppresses osteogenic differentiation of BMSCs during osteoporosis. Cell Death Dis. 2020;13:1511.

69. Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X, et al. Epigenetics and HEC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene. 2014;33:3826–35.

70. Foltz G, Yoon JG, Lee H, Ma L, Tian Q, Hood L, et al. Epigenetic regulation of Wnt pathway antagonists in human pancreatic cancer cells. J Biol Chem. 2015;290:3002–13.
75. Ahmad A, Sarkar SH, Bitar B, Ali S, Aboukameel A, Sethi S, et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol Cancer Ther. 2012;11:2193–201.

76. Danieau G, Morice S, Renault S, Brion R, Bitezau K, Amiaud J, et al. ICG-001, an inhibitor of the beta-catenin and cAMP response element-binding protein dependent gene transcription, decreases proliferation but enhances migration of osteosarcoma cells. Pharmaceuticals (Basel). 2021;14(5):421.

77. Huang Y, Sheng H, Xiao Y, Hu W, Zhang Z, Chen Y, et al. Wnt/beta-catenin inhibitor ICG-001 enhances the anti-tumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma. Radiat Oncol. 2021;16:234–44.

78. Chan LS, Man OY, Kwok HH, Chen L, Chan KC, Lung HL, et al. The Wnt modulator ICG001 mediates the inhibition of nasopharyngeal carcinoma cell migration in vitro via the miR150/CD44 axis. Int J Oncol. 2019;54:1010–20.

79. Manegold P, Lai KY, Wu Y, Teo JL, Lenz HJ, Genyk YS, et al. Differentiation therapy targeting the beta-Catenin/CBP interaction in pancreatic cancer. Cancers (Basel). 2018;10(4):195.

80. Koachdar S, Dong J, Torres M, Rajapakse K, Niklos F, Davis CM, et al. ICG-001 exerts potent anticancer activity against uveal melanoma cells. Invest Ophthalmol Vis Sci. 2018;59:132–43.

81. Zinecker H, Ouaret D, Ebner D, Gaïditt MM, Taylor S, Aulicino A, et al. ICG-001 affects DRP1 activity and ER stress correlated with its anti-proliferative effect. Oncotarget. 2017;8:106764–77.

82. Zhang X, Zheng X, Lou Y, Wang H, Xu J, Zhang Y, et al. beta-catenin inhibitors suppress cells proliferation and promote cells apoptosis in PC9 lung cancer stem cells. Int J Clin Exp Pathol. 2017;10:11968–78.

83. Liu Y, Chen H, Zheng P, Zheng Y, Luo Q, Xie G, et al. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 2017;36:125.

84. Wiese M, Walther N, Diedrichs C, Schil F, Monecke S, Salinas G, et al. The beta-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. Oncotarget. 2017;8:27300–13.

85. Grigson ER, Ozerova M, Pisklakova A, Liu H, Sullivan DM, Nefedova Y. Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner. PLoS ONE. 2015;10(11):76993.

86. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, et al. Small-molecule inhibition of CBP/catenin interaction eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 2014;33:2169–78.

87. Li ZY, Huang GD, Chen L, Zhang C, Chen BD, Li QZ, et al. Tanshinone IIA induces apoptosis via inhibition of Wnt/beta-catenin signaling in AtT20 cells. Mol Med Rep. 2017;16:5908–14.

88. Gotze S, Coersmeyer M, Muller Q, Severs S. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells. Int J Oncol. 2014;45:1715–23.

89. Shi QQ, Zuo GW, Feng QZ, Zhao LC, Luo L, You ZM, et al. Effect of trichostatin A on anti HepG2 liver carcinoma cells: inhibition of HDAC activity and activation of Wnt/beta-Catenin signaling. Asian Pac J Cancer Prev. 2014;15:7849–55.

90. Shin H, Kim JH, Lee YS, Lee YC. Change in gene expression profiles of secreted frizzled-related proteins (SRFPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling. Int J Oncol. 2012;40:1533–42.

91. Bordonaro M, Lazarova DL, Augenlicht LH, Sartorelli AC. Cell type- and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate. Int J Cancer. 2002;97:42–51.

92. Riva G, Calibrari C, Bazzoni R, Cadamuro M, Negron C, Butta V, et al. Valproic acid inhibits proliferation and reduces invasiveness in glioma stem cells through Wnt/beta-catenin signalling activation. Genes (Basel). 2018;9(11):522.

93. Liu S, Liang B, Jia H, Jiao Y, Pang Z, Huang Y. Evaluation of cell death pathways initiated by antitumor drugs melatonon and valproic acid in bladder cancer cells. FEBS Open Bio. 2017;7:798–810.

94. Shao N, Zou J, Li J, Chen F, Dai J, Qu X, et al. Hyper-activation of WNT/beta-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia. Leuk Lymphoma. 2012;53:1769–78.

95. Sikandar S, Dixon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget. 2010;1:596–605.

96. Zhao L, Lv C, Sun L, Li Q, Wang Y, Wu M, et al. Histone deacetylase inhibitor chidamide regulates the Wnt/beta-catenin pathway by MYCN/DKK3 in B-ALL. Invest New Drugs. 2021;39:961–70.

97. Sun N, Zhang L, Zhang C, Yuan Y. miR-144-3p inhibits cell proliferation of colorectal cancer cells by targeting BCL6 in inhibition of Wnt/beta-catenin signaling. Cell Mol Biol Lett. 2020;25:19.

98. Fu Q, Sun Z, Yang F, Mao T, Gao Y, Wang H. SOX30, a target gene of miR-653-5p, represses the proliferation and invasion of prostate cancer cells through inhibition of Wnt/B-catenin signaling. Cell Mol Biol Lett. 2019;24:71.

99. van Schie EH, van Amerongen R. Aberrant WNT/CTNNB1 signaling as a therapeutic target in human breast cancer: weighing the evidence. Front Cell Dev Biol. 2020;8:25.

100. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513–32.

101. Neiheisel A, Kaur M, Ma N, Havard P, Shenoy AK. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials. Int J Cancer. 2022;150(5):727–740.